Manuel Jesus Alcazar Vaca, Toledo (ES); Jose Ignacio Andres Gil, Madrid (ES); Christa C. Chrovian, La Jolla, CA (US); Heather R. Coate, San Diego, CA (US); Meri De Angelis, Munich (DE); Curt A. Dvorak, Poway, CA (US); Christine F. Gelin, San Diego, CA (US); Michael A. Letavic, San Diego, CA (US); Brad M. Savall, San Diego, CA (US); Akinola Soyode-Johnson, San Diego, CA (US); Brice M. Stenne, San Diego, CA (US); and Devin M. Swanson, Carlsbad, CA (US)
Assigned to JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed by JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed on Oct. 18, 2023, as Appl. No. 18/381,554.
Application 18/381,554 is a continuation of application No. 17/576,644, filed on Jan. 14, 2022, granted, now 11,820,770.
Application 17/576,644 is a continuation of application No. 16/911,428, filed on Jun. 25, 2020, granted, now 11,225,478, issued on Jan. 18, 2022.
Application 16/911,428 is a continuation of application No. 16/196,140, filed on Nov. 20, 2018, granted, now 10,703,749, issued on Jul. 7, 2020.
Application 16/196,140 is a continuation of application No. 15/258,320, filed on Sep. 7, 2016, granted, now 10,150,765, issued on Dec. 11, 2018.
Application 15/258,320 is a continuation of application No. 14/714,714, filed on May 18, 2015, granted, now 9,464,084, issued on Oct. 11, 2016.
Application 14/714,714 is a continuation of application No. 14/212,669, filed on Mar. 14, 2014, granted, now 9,066,946, issued on Jun. 30, 2015.
Claims priority of provisional application 61/786,260, filed on Mar. 14, 2013.
Prior Publication US 2024/0116930 A1, Apr. 11, 2024
a therapeutically effective amount of (R*)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl) methanone; and
at least one pharmaceutically acceptable excipient.